Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Lilly Loses UK High Court Alimta Battle

This article was originally published in Scrip

Executive Summary

Eli Lilly & Co. will continue to "vigorously defend" its Alimta (pemetrexed disodium) patents in the UK, France, Italy and Spain, it said, following a UK High Court ruling last week that will allow competitor Actavis to market a generic version of the cancer drug.

Advertisement

Related Content

Lilly CEO ‘Encouraged’ By Trump Meeting As Volume – Not Prices – Drives 4Q Revenue Growth
Lilly Executes Growth Strategy As New Products Drive Sales Gains

Topics

Advertisement
UsernamePublicRestriction

Register

SC064497

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

All set! This Question has been sent to my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Add a personalized Question to your Analyst

Cancel